Zhongshan Medical Novishen New Drug R&D Co., Ltd

Novishen is a biopharmaceutical company headquartered in Zhongshan, China, specializing in the development of next-generation small molecule drugs and protein degraders. The company was founded by Dr. Yuan-Hua Ding, a former executive at Pfizer, and focuses on First-in-class and Best-in-class therapies for oncology and metabolic diseases. Their core research leverages a proprietary protein degradation platform to target previously undruggable proteins, with a lead program focused on USP7. Novishen aims to bridge the gap between basic research and clinical application through its integrated R&D capabilities in the Guangdong-Hong Kong-Macao Greater Bay Area. The company has successfully raised significant venture capital to advance its pipeline of innovative candidates toward clinical trials.